9th IAS Conference on HIV Science

July 23-26, 2017; Paris, France
CCO is the official provider of online scientific analysis for the 2017 International AIDS Society meeting through Capsule Summaries, downloadable slides, rapid expert Webinars, and ClinicalThought commentaries.



Novel unboosted INSTI-based regimen generally well tolerated with no emergent resistance mutations.

Released: July 25, 2017

The 2-drug regimen yielded 90% virologic success at Week 24 in patients with baseline HIV-1 RNA up to 500,000 copies/mL.

Released: July 25, 2017

Encouraging long-term safety and efficacy data continue to support late-stage clinical development of long-acting injectable maintenance regimen.

Released: July 26, 2017

The single-tablet regimen demonstrated a low cumulative rate of virologic rebound through 24 weeks, with few serious AEs and discontinuations due to AEs.

Released: July 26, 2017

Efficacy of switch to INSTI-based regimen noninferior to continued PI treatment at Week 48 in older HIV-infected population with multiple risk factors for cardiovascular disease.

Released: July 27, 2017

In addition to demonstrating comparable efficacy, DOR/3TC/TDF produced significantly fewer neuropsychiatric AEs and had a more favorable impact on fasting lipid levels in comparison with EFV/FTC/TDF.

Released: July 27, 2017

Cabotegravir demonstrates good tolerability in preliminary study of use of this strategy for potential PrEP candidate.

Released: July 27, 2017

HIV-1 RNA < 50 copies/mL in 89% vs 93% of patients at Week 48, with no treatment-emergent resistance mutations in either arm.

Released: July 27, 2017

Lower risk of fracture was associated with cumulative efavirenz exposure, although no causal link found.

Released: July 28, 2017

eGFR was significantly lower with zoledronic acid vs TDF switch, despite improvements in bone mineral density.

Released: July 28, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.